Skip to content
- Genomic and expressional dynamics of ovarian cancer cell lines in PARPi treatment revealed mechanisms of acquired resistance.
- Cheng A, Rao Q, Liu Y, Huo C, Lin Z, Lu H.
- Gynecol Oncol. 2022 Oct 18:S0090-8258(22)01888-1. doi: 10.1016/j.ygyno.2022.10.011. Epub ahead of print.
- Combined inhibition of PARP and EZH2 for cancer treatment: Current status, opportunities, and challenges.
- Zhang X, Huo X, Guo H, Xue L.
- Front Pharmacol. 2022 Oct 3;13:965244. doi: 10.3389/fphar.2022.965244.